Alzheimer's amyloid β interaction with normal human plasma high density lipoprotein: Association with apolipoprotein and lipids

Clinica Chimica Acta

Volumn 270, Issue 2, 1998, Pages 75-84

  Koudinov, Alexei R ^a,b,c,e   Berezov, Temirbolat T ^a,c   Kumar, Asok ^d   Koudinova, Natalia V ^a,c,d  

^a PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^b MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

^c INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Alzheimer's disease; Amyloid beta protein; Apolipoprotein; Biotinylation; High density lipoprotein; Lipid

Indexed keywords

AMYLOID BETA PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; SYNTHETIC PEPTIDE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; ULTRACENTRIFUGATION;

ADULT; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS; BINDING SITES; BIOTINYLATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOBLOTTING; LIPIDS; LIPOPROTEINS, HDL; MICROSCOPY, ELECTRON; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS;

EID: 0032559575     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(97)00207-6     Document Type: Article

References (35)

1. [1] Glenner G, Wong C. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-90.
2. [2] Pettegrew J, Klunk W, McClure R, Panchalingam K, Strychor S. Phosphomonoesters, phospholipids, and high-energy phosphates in Alzheimer's disease: alterations and physiological significance. In: Khachuturian Z, Blass J, editors. Alzheimer's disease. New treatment strategies. New York: Marcel Dekker Inc., 1988:200-5.
3. [3] Selkoe D. Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease. Trends in Neurosci 1993;16:403-9.
4. [4] Koudinov A, Koudinova N. Soluble amyloid beta protein is secreted by HepG2 cells as an apolipoprotein. Cell Biol Internat 1997;25:265-71.
5. [5] Levy E, Carman M, Fernandez-Madrid I et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral haemorrhage, Dutch-type. Science 1990;248:1124-6.
6. [6] Hilbich C, Kisters-Woike B, Reed J, Masters C, Beyreuther K. Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's Disease. J Mol Biol 1991;218:149-63.
7. [7] Burdick D, Soreghan B, Kwon M et al. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J Biol Chem 1992;267:546-54.
8. [8] Snyder S, Ladror U, Wade W et al. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 1994;67:1216-28.
9. [9] Strittmatter W, Saunders A, Schmechel D et al. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-81.
10. [10] Schwarzman A, Gregori L, Vitek M et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 1994;91:8368-72.
11. [11] Ma J, Yee A, Brewer H, Das S, Potter H. Amyloid-associated proteins α-1-antichymotripsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994;372:92-4.
12. [12] Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J - Alzheimer's Aβ interaction. J Biol Chem 1995;270:7563-7.
13. [13] Koudinov A, Matsubara E, Frangione B, Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 1994;205:1164-71.
14. [14] Koudinov A, Koudinova N, Kumar A. Is amyloid beta an apolipoprotein? In: Neuroscience meeting abstract book. New York: New York University Medical Center, 1995:103.
15. [15] Koudinov A, Koudinova N, Kumar A, Beavis R, Ghiso J. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun 1996;223:592-7.
16. [16] Koudinova N, Koudinov A, Berezov T. Amyloid β in plasma and cerebrospinal fluid is associated with high density lipoproteins. Vopr Med Khim 1996;42:253-62.
17. [17] Davis R. Lipoprotein structure and secretion. In: Vance D, Vance J, editors. Biochemistry of lipids, lipoproteins and membranes. Amsterdam: Elsevier Science Publishing Co., 1991:403-26.
18. [18] Koudinova N, Koudinov A, Kumar A, Berezov T. Amyloid beta binding to lipids and apolipoproteins of the HDL. Eur Psych 1997;2:212s.
19. [19] Koudinova N, Koudinov A, Kumar A, Berezov T. Alzheimer's Amyloid β interaction with the HDL: association with apolipoproteins and lipids. FASEB J 1997;11:A961.
20. [20] Koudinov A, Koudinova N, Berezov T. Alzheimer's peptides Aβ1-40 and Aβ1-28 inhibit the plasma cholesterol esterification rate. Biochem Mol Biol Internat 1996;38:747-52.
21. [21] Folch J, Lees J, Sloane S. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem 1957;226:497-509.
22. [22] Bradley WA, Gianturco SH. Lipoprotein receptors in cholesterol metabolism. In: Yeagle P, editor. Biology of cholesterol. Boca Raton, Florida: CRC Press, Inc., 1988:95-119.
23. [23] Scanu AM, Edelstein C, Shen B. Plasma Lipoproteins. In: Jost P, Griffith O, editors. Lipid-protein interactions. New York: John Wiley and Sons, 1982:268-307.
24. [24] Koudinov A, Koudinova N, Kumar A, Beavis R, Ghiso J. Alzheimer's soluble amyloid beta protein is associated with high density lipoproteins in normal human cerebrospinal fluid and is secreted by HepG2 cells as a part of lipoprotein complexes. Soc Neurosci Abstr 1996;22:2118.
25. [25] Puchtler H, Sweat F, Levine M. On the binding of Congo Red by amyloid. J Histochem Cytochem 1962;10:355-64.
26. [26] Koudinov A. Amyloid beta as an apolipoprotein of high density lipoprotein 3 and very high density lipoprotein. Moscow: Russian Peoples' Friendship University, 1994:69-74.
27. [27] Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 1996;316:671-9.
28. [28] Frangione B, Castano E, Prelli F, Soto C, Ghiso J, Wisniewski, T. Chaperoning amyloid in Alzheimer's disease: the art of avoiding sticky situations? In: Roses A, Weisgraber K, Christen Y, editors. Apolipoprotein E and Alzheimer's disease. Berlin: Springer, 1996:151-60.
29. [29] Moore M, McCarthy M. Lipid binding and insertion by full-length and truncated Alzheimer's β-amyloid peptides. Biophys J 1994;66:A384.
30. [30] Davis R. Lipoprotein structure and secretion. In: Vance D, Vance J, editors. Biochemistry of Lipids, lipoproteins and membranes, Amsterdam: Elsevier Science Publishing Co., 1991:403-26.
31. [31] Segrest J, Jackson R, Morrisett J, Gotto A. A molecular theory of lipid-protein interaction in the plasma lipoproteins. FEBS Lett 1974;38:247-53.
32. [32] Soreghan B, Kosmoski J, Glabe C. Surfactant properties of Alzheimer's Aβ peptides and the mechanism of amyloid aggregation. J Biol Chem 1994;269:28551-4.
33. [33] Husebekk A, Skogen B, Husby G. Characterization of amyloid proteins AA and SAA as apolipoproteins of high density lipoprotein (HDL). Scand J Immunol 1987;25:375-81.
34. [34] Nichols W, Dwulet F, Liepnieks J, Benson M. Variant apolipoprotein A-I as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun 1988;156:762-8.
35. [35] Sparrow J, Sparrow D, Fernando G, Culwell A, Kovar M, Gotto A. Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus. Biochemistry 1992;31:1065-8.